U.S. pharma huge copyright scrapped two experimental weight loss supplements final year—a at the time-day-to-day capsule, lotiglipron, because of elevated liver enzymes in addition to a twice-each day tablet, danuglipron, because of powerful Unwanted side effects—but CEO Albert Bourla has claimed the company is decided to “play and acquire”